Van Andel Institute scientists and collaborators have developed a new method for identifying and classifying pancreatic cancer cell subtypes based on sugars found on the outside of cancer cells.
22 minutes ago
0
0
Immune checkpoint inhibitors, a class of immunotherapies that help immune cells attack cancer more effectively, have revolutionized cancer treatment. However, fewer than 20% of patients respond to these treatments, highlighting ...
20 hours ago
0
12
Chinese scientists have revealed a hidden metabolic partnership between breast cancer cells and immune cells that drives aggressive tumor behavior and resistance to immunotherapies. The study sheds light on how tumor cells ...
Apr 7, 2025
0
22
Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors—a smart fighter that destroys cancer cells for days without tiring. USC biomedical engineers have made this concept a reality, ...
Apr 2, 2025
0
54
Researchers at the University of Kentucky analyzed different factors that could explain the high mortality rates of colorectal cancer in Appalachian Kentucky.
Apr 2, 2025
0
0
Obesity is associated with an increased risk of developing breast cancer, and a greater probability for the cancer to spread to other organs. But the causes of this association are still not well understood. Researchers at ...
Apr 2, 2025
0
67
Gastric cancer (GC) is a leading cause of cancer-related deaths worldwide, with more than one million new diagnoses annually. Unfortunately, many cases are detected at advanced stages due to the lack of clear early symptoms, ...
Apr 1, 2025
0
0
A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment's effectiveness in patients with metastatic gastrointestinal cancers, according to ...
Apr 1, 2025
0
31
A pan-Canadian team has developed a new way to quickly find personalized treatments for young cancer patients, by growing their tumors in chicken eggs and analyzing their proteins.
Apr 1, 2025
0
7
The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated advanced neuroendocrine tumors, offering a new standard of care for this ...
Mar 31, 2025
0
0
